Karen M. Knitowski

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski et al. · Psychopharmacology · 2007 · 156 citations

Molecular Pharmacology, Psychoactive Drug, Psychiatric Disorders +14

Role for M₅ muscarinic acetylcholine receptors in cocaine addiction

Anders Fink‐Jensen, Irina Fedorova, Gitta Wörtwein et al. · Journal of Neuroscience Research · 2003 · 125 citations

Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344

Linda M. Rorick‐Kehn, E.J. Perkins, Karen M. Knitowski et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 67 citations

The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain

Caterina Montani, Carola Canella, Adam J. Schwarz et al. · Neuropsychopharmacology · 2020 · 53 citations · Full text

Nmdar Antagonist-induced Changes, Neurophysiology, Neuroanatomy +11

Preclinical findings predicting efficacy and side‐effect profile of <scp>LY</scp> 2940094, an antagonist of nociceptin receptors

Jeffrey M. Witkin, Linda M. Rorick‐Kehn, Mark J. Benvenga et al. · Pharmacology Research & Perspectives · 2016 · 31 citations · Full text